Combined therapy: what does acamprosate and naltrexone combination tell us?

TY - JOUR

T1 - Combined therapy: what does acamprosate and naltrexone combination tell us?

AU - Kiefer, Falk

AU - Wiedemann, Klaus

PY - 2004

Y1 - 2004

N2 - AIMS: Relapse prevention treatment with both acamprosate and naltrexone has been shown to be efficacious in the treatment of alcoholism. Whereas both compounds act pharmacologically differently, there is up to now only limited evidence as to whether combined treatment is efficacious and pharmacologically safe. It remains to be answered whether data justify the combination of both drugs in clinical practice. METHODS: Review of the three pre-clinical and four clinical studies that have been published to date on either combined tolerability or efficacy. RESULTS: Data available up to now show no occurrence of severe adverse events during combined treatment. Diarrhoea and nausea were shown to be the most significant side-effects. Whereas pre-clinical studies regarding efficacy of combined treatment are not yet conclusive, clinical data show the superiority of combined treatment compared with both placebo and acamprosate monotherapy. The synergistic effect of combined treatment remained after 12 weeks of drug-free follow-up. CONCLUSIONS: The combination of acamprosate with naltrexone in a clinical sample seems to be efficacious and safe. Numerous alcohol dependent patients could benefit, particularly those that responded insufficiently on monotherapeutic treatment with either acamprosate or naltrexone.

AB - AIMS: Relapse prevention treatment with both acamprosate and naltrexone has been shown to be efficacious in the treatment of alcoholism. Whereas both compounds act pharmacologically differently, there is up to now only limited evidence as to whether combined treatment is efficacious and pharmacologically safe. It remains to be answered whether data justify the combination of both drugs in clinical practice. METHODS: Review of the three pre-clinical and four clinical studies that have been published to date on either combined tolerability or efficacy. RESULTS: Data available up to now show no occurrence of severe adverse events during combined treatment. Diarrhoea and nausea were shown to be the most significant side-effects. Whereas pre-clinical studies regarding efficacy of combined treatment are not yet conclusive, clinical data show the superiority of combined treatment compared with both placebo and acamprosate monotherapy. The synergistic effect of combined treatment remained after 12 weeks of drug-free follow-up. CONCLUSIONS: The combination of acamprosate with naltrexone in a clinical sample seems to be efficacious and safe. Numerous alcohol dependent patients could benefit, particularly those that responded insufficiently on monotherapeutic treatment with either acamprosate or naltrexone.

M3 - SCORING: Zeitschriftenaufsatz

VL - 39

SP - 542

EP - 547

JO - ALCOHOL ALCOHOLISM

JF - ALCOHOL ALCOHOLISM

SN - 0735-0414

IS - 6

M1 - 6

ER -